Cadent Therapeutics, Inc.

Cadent Therapeutics, Inc.

Cadent Therapeutics, Inc.

Date Founded



400 Technology Square,10th floor,Cambridge, MA 02139

Type of Company


Employees (Worldwide)

1 - 10


Holding Companies

Company Description

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Cadent Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Director

Executive Director, Business Development

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Head-Discovery Operations

Director-Vitro Pharmacology

Vice President-Chemistry

Vice President, Regulatory Affairs & Quality Assurance

Vice President, Finance & Administration

Board of Directors

Chief Executive Officer & Director at Cadent Therapeutics, Inc.

Senior Advisor, Life Sciences Team at Frazier Healthcare Partners

Chief Executive Officer & Director at Obsidian Therapeutics, Inc.

Co-Founder at Cognition Therapeutics, Inc.

Chief Executive Officer & Director at Ataxion, Inc.

Advisor at Atlas Venture, Inc.

Paths to Cadent Therapeutics, Inc.
Potential Connections via
Relationship Science
Cadent Therapeutics, Inc.
Recent Transactions
Details Hidden

Slater Technology Fund, Inc., Clal Biotechnology Industries Ltd. (Venture Capital), Cadent Therapeutics, Inc. purchase Ataxion, Inc. from Atlas Venture, Inc.

Details Hidden

Cadent Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onSlater Technology Fund, Inc., Clal Biotechnology Industries Ltd. (Venture Capital), Cadent Therapeutics, Inc. purchase Ataxion, Inc. from Atlas Venture, Inc.

Details Hidden

Cowen Investment Management LLC is the global investment management business of Cowen Inc. Cowen Investment Management provides alternative asset management solutions to a global client base and manages a significant portion of Cowen’s proprietary capital.

Details Hidden

CBI-VC is a hands-on, long-term manager which prefers to invest in Israeli biotechnology companies.The firm seeks to invest in companies with a seasoned management team, proprietary biopharmaceutical solutions to unmet clinical needs, clinical proof of concept and large potential markets.CBI-VC partners with their investee companies, providing help in the recruitment of management executives and advisors, identifying complementary technology and products, negotiating agreements and developing strategies ensuring successful follow-up financing.The firm seeks to participate in additional financing rounds and to secure financing rights within potential subsidiaries and priority rights regarding future investee company spin-offs.

Details Hidden

Atlas Venture focuses on investments in early-stage companies operating in the fields of biotechnology. The firm partners with entrepreneurs to build companies around innovative science.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cadent Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cadent Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cadent Therapeutics, Inc..